We are committed to leveraging our intellectual property and the product development expertise of our highly experienced management team to enable vascular targeted therapy to realize its true potential and to bring much needed new therapies for orphan oncology indications to cancer patients worldwide. We have a portfolio of preclinical and clinical stage candidates focused on areas of significant unmet need that we believe can bring significant value to our shareholders.
Our common stock is traded on the OTCQX Market under the symbol “MATN”.
We are headquartered in South San Francisco, California.
Events & Presentations
Feb 13, 2017 at 5:30 PM ET
BIO CEO & Investor Conference
Sep 27, 2016 at 4:00 PM ET
Ladenburg Thalmann 2nd Annual Healthcare Conference